Cagrilintide is a synthetic peptide that mimics a hormone called amylin, and it's being developed as a powerful weight loss treatment. When paired with another peptide called semaglutide, this combination is showing remarkable results in clinical trials — people are losing an average of 22% of their body weight, which rivals what you'd see with weight loss surgery. That's why researchers are so excited about it as the next breakthrough in obesity treatment.
Think of your brain as having multiple control centers that manage hunger and fullness, like having several thermostats in different rooms of your house. Cagrilintide works by activating specific receptors in your brain's satiety centers, essentially telling you "I'm full" much sooner during meals. Meanwhile, semaglutide works through a different pathway, slowing down how quickly food leaves your stomach and hitting separate appetite circuits in your brain. It's like having two different friends both convincing you to stop eating, but for different reasons.
What makes this combination so effective is that these two pathways work together without completely overlapping — they're hitting your body's hunger signals from multiple angles simultaneously. Your brain gets clearer, stronger messages about fullness and satisfaction, leading to naturally eating less without the constant battle against cravings.
Dosage Information
Typical Dose
0.3-2.4 mg weekly (Phase 3 trial doses)
Frequency
Once weekly
Administration
Subcutaneous injection
Half-Life
7–8 days
Notes
Not yet FDA approved — currently in Phase 3 trials. This entry documents the research context. Commercial availability expected 2025-2026 pending regulatory approval.
Why this matters
Long-acting amylin analog; once-weekly dosing.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Draw to the
12
unit mark
Draw 12 units for your 300mcg dose of Cagrilintide
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Cagrilintide sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.74
Compound Data
Molecular Formula
C194H312N54O59S2
Molecular Weight
4409.00 g/mol
IUPAC Name
20-[[(1S)-4-[[(2S)-6-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R,3S)-1-[[(2R)-4-amino-1-[[(2R)-1-[[2-[[(2R)-1-[[(2R)-4-amino-1-[[(2R,3S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-16-(2-amino-2-oxoethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
PubChem CID
171397054Potential Side Effects
Cagrilintide discussions
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 0.3-2.4 mg weekly (Phase 3 trial doses)
- Frequency
- Once weekly
- References
- 0 curated + 42 from PubMed
- Clinical Trials
- 32 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Cagrilintide
What is Cagrilintide?
Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk that is currently in Phase 3 clinical trials in combination with semaglutide (the combination called CagriSema) for obesity treatment. Early trial data has shown average weight loss of 22% of body weight — approaching the efficacy of bariatric surgery — making it one of the most anticipated metabolic peptide therapeutics in development. Cagrilintide represents the next generation of anti-obesity pharmacotherapy combining amylin receptor agonism with GLP-1 receptor agonism for enhanced efficacy.
How does Cagrilintide work?
Cagrilintide is a fatty-acid modified amylin analog with a half-life of approximately one week enabling once-weekly dosing. It acts through amylin receptors in the hypothalamus and brainstem producing satiety signaling that complements GLP-1 receptor agonism through distinct but synergistic pathways. Amylin receptor activation reduces meal size through direct satiety center effects while GLP-1 receptor activation slows gastric emptying and reduces appetite through separate hypothalamic circuits. The combination produces greater weight loss than either mechanism alone because the two pathways converge on food intake regulation without complete overlap. In Phase 3 trials the CagriSema combination (cagrilintide 2.4mg + semaglutide 2.4mg weekly) has demonstrated 22-25% mean weight loss at 68 weeks.
What is the recommended dosage for Cagrilintide?
The typical dose is 0.3-2.4 mg weekly (Phase 3 trial doses). Once weekly. Administration: Subcutaneous injection. Not yet FDA approved — currently in Phase 3 trials. This entry documents the research context. Commercial availability expected 2025-2026 pending regulatory approval.
What are the side effects of Cagrilintide?
Nausea (very common during dose escalation). Vomiting (common). Diarrhea (common). Constipation (common). Injection site reactions (uncommon)
What is the Cagrilintide cycle protocol?
Cagrilintide is typically cycled ongoing. Weekly subcutaneous injection, Phase 3 trial protocol
Questions reflect common community inquiries. This is not medical advice.